Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.

Antimicrobial agents and chemotherapy - 1 Jan 2017

Aouri Manel, Barcelo Catalina, Guidi Monia, Rotger Margalida, Cavassini Matthias, Hizrel Cédric, Buclin Thierry, Decosterd Laurent A, Csajka Chantal

Abstract excerpt

Rilpivirine (RPV), the latest nonnucleoside reverse transcriptase inhibitor active against HIV-1, is prescribed in a standard dosage of 25 mg once a day in combination with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). The aim of this observational study was to characterize the RPV pharmacokinetic profile, to quantify interpatient variability, and to identify potential factors that could influence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP3A

Share to Glucuronosyltransferase

Share to HIV Infections

Share to Rilpivirine

Source

Open in PubMed Open full text

Identifiers

PMID: 27799217
DOI: 10.1128/AAC.00899-16
PMCID: PMC5192124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.PMID 27799217Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.Semantic proximity Read ↗

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patientsSemantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

Dosage optimization of treatments using population pharmacokinetic modeling and simulation.Semantic proximity Read ↗

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.Semantic proximity Read ↗

Influence of <i>ABCC2</i> and <i>ABCC4</i> Polymorphisms on Tenofovir Plasma Concentrations in Thai HIV-Infected PatientsSemantic proximity Read ↗

Population Approach to Efavirenz Therapy.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Semantic proximity Read ↗

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.